Unveiling intratumoral microbiota: An emerging force for colorectal cancer diagnosis and therapy

• Main Authors: Jinjing Zhang (Author), Penghui Wang (Author), Jiafeng Wang (Author), Xiaojie Wei (Author), Mengchuan Wang (Author)
• Format: Book
• Published: Elsevier, 2024-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 1096-1186; 10.1016/j.phrs.2024.107185
• Keywords: Tumor microbiome; Microbial biomarker; Gastrointestinal cancer; Gut microbiota; Cancer treatment; Immunotherapy; Therapeutics. Pharmacology; RM1-950
• Source: Pharmacological Research, Vol 203, Iss , Pp 107185- (2024)

Microbes, including bacteria, viruses, fungi, and other eukaryotic organisms, are commonly present in multiple organs of the human body and contribute significantly to both physiological and pathological processes. Nowadays, the development of sequencing technology has revealed the presence and composition of the intratumoral microbiota, which includes Fusobacterium, Bifidobacteria, and Bacteroides, and has shed light on the significant involvement in the progression of colorectal cancer (CRC). Here, we summarized the current understanding of the intratumoral microbiota in CRC and outline the potential translational and clinical applications in the diagnosis, prevention, and treatment of CRC. We focused on reviewing the development of microbial therapies targeting the intratumoral microbiota to improve the efficacy and safety of chemotherapy and immunotherapy for CRC and to identify biomarkers for the diagnosis and prognosis of CRC. Finally, we emphasized the obstacles and potential solutions to translating the knowledge of the intratumoral microbiota into clinical practice.